The Role of Microparticles as a Biomarker in Distinguishing Between Thrombotic Thrombocytopenic Purpura (TTP) and Atypical Hemolytic Uremic Syndrome (aHUS)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Atypical Hemolytic Uremic Syndrome
- Sponsor
- University of Rochester
- Locations
- 1
- Primary Endpoint
- Microparticle/Nanoparticle number (an absolute number)
- Status
- Withdrawn
- Last Updated
- 7 years ago
Overview
Brief Summary
The investigators propose to characterize MPs in aHUS and TTP both at the onset and throughout treatment. The investigators believe that the number, size, and cell origin of MPs will differ between these two diseases. The hypothesis is that endothelial derived MPs will be higher in number and comprise a larger portion of the MP population in aHUS and that platelet MPs will comprise a larger number and greater proportion of MPs in TTP. The investigators believe that MP identity and number can be used to reliably differentiate between aHUS and TTP at disease onset.
Investigators
Majed Refaai
Associate Professor
University of Rochester
Eligibility Criteria
Inclusion Criteria
- •Patients with MAHA, TTP, and/or aHUS
Exclusion Criteria
- •Prisoners
Outcomes
Primary Outcomes
Microparticle/Nanoparticle number (an absolute number)
Time Frame: an average of 3 months
Microparticle/Nanoparticle size (in nanometers or micrometers)
Time Frame: an average of 3 months
Microparticle/Nanoparticle identity (identity of cell type from which they are derived)
Time Frame: an average of 3 months
Secondary Outcomes
- Morbidities(3 months)
- Mortality(3 months)